The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis

被引:4
|
作者
Li, Xiaoyan [1 ]
He, Jie [2 ,3 ]
Sun, Qiuhua [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Nursing, 548 Binwen Rd, Hangzhou 310000, Zhejiang, Peoples R China
[2] Chengdu Med Coll, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Chengdu 610500, Sichuan, Peoples R China
[3] Chengdu Med Coll, Clin Med Coll, Chengdu 610500, Sichuan, Peoples R China
关键词
Sarcopenia; Metabolic dysfunction-associated steatotic; liver disease (MASLD); Prevalence; Systematic review; Meta-analysis; INSULIN-RESISTANCE; FIBROSIS; NAFLD; RISK; STEATOHEPATITIS; QUALITY;
D O I
10.1016/j.clnu.2024.07.006
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background and aims: Sarcopenia is a common complication in patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). However, the prevalence and its impact on the survival of sarcopenia in patients with MASLD is unknown. In this study, we aimed to assess the prevalence and effects of sarcopenia in patients with MASLD. Methods: Systematic review and meta-analysis of full texts of relevant studies were searched from inception until June 12, 2024 in five databases (PubMed, Cochrane Library, Embase, Web of Science, and the China National Knowledge Infrastructure). Next, we assessed the prevalence of sarcopenia in MASLD, and calculated the ORs and HRs between sarcopenia and MASLD based on the adjusted data from individual studies. Statistical analyses were performed using Stata 11.0. Results: Of the 2984 records considered, 29 studies recruiting 63,330 patients were included. The pooled prevalence of sarcopenia in patients with MASLD was 23.5% overall (95% CI; 19.1%-27.9%, I2 = 99.6%), and was higher in Asian patients, male, cross-sectional studies, when BIA were employed to measure muscle mass, one criterion of diagnosis sarcopenia, MASLD was diagnosed employing MRI, and moderate-quality studies. Sarcopenia was associated with MASLD patients (adjusted odds ratio [aOR] 2.08, 95% CI 1.58 -2.74, I2 = 93.6%) with similar findings in subgroups stratified by age, study design, methods for measuring muscle mass, assessment method to detect sarcopenia, and study quality. The association between all-cause mortality further supports the association between sarcopenia and poor prognosis with MASLD (aHR 1.59, 95% CI 1.33-1.91, I2 = 0%). Conclusions: Sarcopenia was strongly associated with MASLD progression and was a risk factor not only for MASLD pathogenesis but was also markedly correlated with MASLD-associated mortality. (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2005 / 2016
页数:12
相关论文
共 50 条
  • [1] Relationship between sarcopenia and metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Malik, Adnan
    Javaid, Sadia
    Malik, Muhammad Imran
    Qureshi, Shahbaz
    ANNALS OF HEPATOLOGY, 2024, 29 (06)
  • [2] Reply-Letter to the editor-The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
    Li, Xiaoyan
    Sun, Qiuhua
    CLINICAL NUTRITION, 2024, 43 (12) : 231 - 232
  • [3] EFFICACY AND SAFETY OF RESMETIROM IN TREATING PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD): A SYSTEMATIC REVIEW AND META-ANALYSIS
    Ekreer, Moad
    Al Hayek, Mohammad
    Alhateem, Mohamed Salah
    Khashan, Abdallah
    Abeedah, Raja
    Aghneewah, Omar
    Abduljawad, Fatimah Alzahra
    Elhadi, Muhammed
    HEPATOLOGY, 2024, 80
  • [4] The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis
    Lv, Qiong
    Zhao, Huashan
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [5] Electrocardiographic abnormalities in patients with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
    Dimala, Christian Akem
    Nso, Nso
    Wasserlauf, Jeremiah
    Njei, Basile
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)
  • [6] Prevalence and significance of autoantibodies in children with metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
    Bolia, Rishi
    Goel, Akhil
    Semwal, Pooja
    Srivastava, Anshu
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024, 79 (03): : 667 - 673
  • [7] Efficacy of the Mediterranean diet in treating metabolic dysfunction-associated steatotic liver disease (MASLD) in children and adolescents: a systematic review and meta-analysis
    Jamil, Asma
    Chivese, Tawanda
    Elshaikh, Usra
    Sendall, Marguerite
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [8] Effects of silymarin use on liver enzymes and metabolic factors in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Malik, Adnan
    Malik, Muhammad
    Qureshi, Shahbaz
    CANADIAN LIVER JOURNAL, 2024, 7 (01): : 40 - 53
  • [9] Effectiveness of Bariatric Surgeries for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis
    AlRumaih, Abdullah Sulaiman
    Alzelfawi, Lama Abdullah
    Alotaibi, Ghadah Khalid
    Aldayel, Osamah AbdulAziz
    Almutairi, Abdulrahman Khazzam
    Alnowaimi, Rosana Tariq
    Alshahrani, Mubarak Mohammed
    Alsharif, Rifal Sami
    Almadani, Sarah Nabil
    SURGERIES, 2024, 5 (03): : 486 - 498
  • [10] Arterial stiffness as a complication of metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis
    Giannakodimos, Alexios
    Oikonomou, Evangelos
    Pantelidis, Panteleimon
    Theofilis, Panagiotis
    Katsiki, Niki
    Goliopoulou, Athina
    Zakynthinos, Georgios E.
    Korakas, Emmanouil
    Kalogera, Vasiliki
    Banach, Maciej
    Lampadiari, Vaia
    Kassi, Eva
    Ikonomidis, Ignatios
    Siasos, Gerasimos
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (04) : 413 - 426